{"id":390336,"date":"2019-10-31T00:00:00","date_gmt":"2019-10-31T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2019-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-and-forecast-g7-2019\/"},"modified":"2026-05-13T11:36:54","modified_gmt":"2026-05-13T11:36:54","slug":"dlsfon0010-2019-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-and-forecast-g7-2019","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2019-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-disease-landscape-and-forecast-g7-2019\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck | Disease Landscape and Forecast | G7 | 2019"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><\/p>\n<p>Treatment for recurrent or metastatic squamous cell carcinoma of the head and neck (<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>) has remained relatively unchanged in the past ten years, and Erbitux-based regimens continue to be the mainstay of treatment. However, immune checkpoint inhibitors are revolutionizing the treatment algorithm for this patient population with the 2016 \/ 2018 approvals of Merck &#038; Co.\u2019s Keytruda and Bristol-Myers Squibb \/ Ono Pharmaceutical\u2019s Opdivo for previously treated recurrent or metastatic\u00a0<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>. Although\u00a0<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>\u00a0has historically proved to be a complex challenge for drug developers, many immune-oncology approaches and other drug classes are competing in late-phase development for\u00a0<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>, both in the metastatic setting and in earlier stages of the disease. Several agents are being positioned for the untapped and lucrative locoregionally advanced\u00a0<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>\u00a0setting and are also poised to contribute to the robust market growth over the 2018-2028 forecast period.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>How large <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854611268978983511665\">are<\/gwmw> the clinically and commercially relevant drug-treatable\u00a0<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>\u00a0populations, and how <gwmw class=\"ginger-module-highlighter-mistake-type-2\" id=\"gwmw-15854611268975539289843\">will<\/gwmw> drug-treatment rates change over time?<\/li>\n<li>What is the current state of treatment for recurrent or metastatic\u00a0<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>?\u00a0What are interviewed experts\u2019 views on these therapies?<\/li>\n<li>Which pipeline products are poised to become options for the treatment of\u00a0<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>, and what sales \/ uptake could they secure?<\/li>\n<li>What are the key drivers and constraints in the\u00a0<abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>\u00a0market, and how will the major markets evolve over the ten-year forecast period?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides <gwmw class=\"ginger-module-highlighter-mistake-type-3\" id=\"gwmw-15854611316195187059621\">comprehensive market intelligence<\/gwmw> with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390336","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-geography-us","biopharma-date-931"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390336\/revisions"}],"predecessor-version":[{"id":576592,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390336\/revisions\/576592"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}